Format

Send to

Choose Destination
Eur Heart J. 2016 Jul 7;37(26):2029-36. doi: 10.1093/eurheartj/ehw027. Epub 2016 Feb 22.

Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial.

Author information

1
Department of Neurology, Bern University Hospital, Bern 3010, Switzerland heinrich.mattle@bluewin.ch.
2
University Hospital of Münster, Münster, Germany.
3
Brighton and Sussex University Hospitals, Brighton, UK.
4
Hotchkiss Brain Institute, University of Calgary, Foothills Hospital, Calgary, AB, Canada.
5
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
6
Davisville Medical Centre, Toronto, ON, Canada.
7
Kiel Migraine and Headache Centre, Kiel, Germany.
8
Toronto General Hospital, Toronto, ON, Canada.
9
University Hospitals of South Manchester, Manchester, UK.
10
Salford Royal Hospitals, Salford, UK.
11
Department of Neurology, Bern University Hospital, Bern 3010, Switzerland.
12
Department of Cardiology, Bern University Hospital, Bern 3010, Switzerland.

Abstract

AIMS:

Migraine with aura and patent foramen ovale (PFO) are associated. The Percutaneous Closure of PFO in Migraine with Aura (PRIMA) trial is a multicentre, randomized trial to investigate the effect of percutaneous PFO closure in patients refractory to medical treatment.

METHODS:

Migraine with aura patients and PFO who were unresponsive to preventive medications were randomized to PFO closure or medical treatment. Both groups were given acetylsalicylic acid 75-100 mg/day for 6 months and clopidogrel 75 mg/day for 3 months. The primary endpoint was reduction in monthly migraine days during months 9-12 after randomization compared with a 3-month baseline phase before randomization. The committee reviewing the headache diaries were blinded to treatment assignment.

RESULTS:

One hundred and seven patients were randomly allocated to treatment with an Amplatzer PFO Occluder (N = 53) or control with medical management (N = 54). The trial was terminated prematurely because of slow enrolment. Eighty-three patients (40 occluder, 43 control) completed 12-month follow-up. Mean migraine days at baseline were 8 (±4.7 SD) in the closure group and 8.3 (±2.4) in controls. The primary endpoint was negative with -2.9 days after PFO closure vs. -1.7 days in control group (P = 0.17). Patent foramen ovale closure caused five adverse events without permanent sequelae.

CONCLUSION:

In patients with refractory migraine with aura and PFO, PFO closure did not reduce overall monthly migraine days.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00505570.

KEYWORDS:

Migraine; Migraine with aura; Patent foramen ovale; Patent foramen ovale closure

Comment in

PMID:
26908949
DOI:
10.1093/eurheartj/ehw027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center